Physician profile
Matthew Gary Sharp
NPI 1548824394
$3,952.65
in general payments reported to CMS, 2019-2025
9 companies · $1,664 in 2025
The $1,664 reported for 2025 was more than what 82% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $120 · 2024: $2,168 · 2025: $1,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,053 · Food and Beverage: $1,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,052.93 |
| Food and Beverage | $1,779.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,132.88 | 2024-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Inceptiv |
| Boston Scientific Corporation | $946.79 | 2024-2025 | Wavewriter Alpha Prime 16, Intracept, General - Therapies |
| Stryker Corporation | $395.34 | 2024 | Augment Injectable |
| Spr Therapeutics, INC | $212.81 | 2025 | Sprint Pns System |
| Abbvie INC. | $120.37 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $83.29 | 2024-2025 | |
| Globus Medical, INC. | $21.93 | 2025 | Senza |
| Collegium Pharmaceutical, INC. | $19.89 | 2025 | Belbuca |
| Averitas Pharma INC. | $19.35 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.